Pathology & Laboratory Medicine

You are here

Oncogenic Transcription Factors in Prostate Cancer

David Rickman, PhD, Principal Investigator

The Oncogenic Transcription Factors in Prostate Cancer laboratory is focused on elucidating the role of oncogenic transcription factors (e.g. ETS family members and N-Myc) in coordinating gene regulation, chromatin 3D architecture and response to chemotherapy in the context of prostate adenocarcinoma and neuroendocrine prostate cancer.

Active Projects

  • The role of ERG in mediating taxane resistance.
  • The role of N-Myc in driving the neuroendocrine prostate cancer phenotype.
  • Development of in vitro and in vivo model systems of oncogenic transcription factor over-expression and other genomic alterations in prostate cancer.

Active Grants

  • Janssen-Challenge Award
    Prostate Cancer Foundation
    “Targeting and mechanistic insights underlying N-Myc driven Neuroendocrine Prostate Cancer”
    The aim of this study is to characterize the driving role of N-Myc and AURKA in neuroendocrine prostate cancer with the ultimate goal of more effectively targeting this tumor subclass by disrupting this complex.
    Role: PI
  • 1R01CA179100-01A1
    NIH-National Cancer Institute
    “Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resistant Prostate Cancer”
    The aim of this study is to characterize the mechanism underlying ERG-induced taxane resistance in castrate resistant prostate cancer.
    Role: PI

Selected Publications

ERG induces taxane resistance in castration-resistant prostate cancer.

David Rickman, PhD

ERG induces taxane resistance in castration-resistant prostate cancer.

Nat Commun. 2014 Nov 25;5:5548. 

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS. 

PubMed PMID: 25420520; PMCID: PMC4244604

Read More

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

David Rickman, PhD

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Urol Oncol. 2013 Jul;31(5):566-71. 

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

PMID: 21600800

Read More

Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer

David Rickman, PhD

Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer

Cell Cycle. 2012 Sep 15;11(18):3380-3.

Elemento O, Rubin MA, Rickman DS.  

PMID: 22918253; PMCID: PMC3466547

Read More

Oncogene-mediated alterations in chromatin conformation

David Rickman, PhD

Oncogene-mediated alterations in chromatin conformation

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8.

Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA.

PMID: 22615383; PMCID: PMC3384175

Read More

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing

David Rickman, PhD

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing

Genome Res. 2011 Jan;21(1):56-67.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY, Cao X, Barrette T, Tewari AK, Chee MS, Chinnaiyan AM, Rickman DS, Demichelis F, Gerstein MB, Rubin MA.

PMID: 21036922; PMCID: PMC3012926

Read More

ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression

David Rickman, PhD

ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression

Neoplasia. 2010 Dec;12(12):1031-40.

Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F.

PMID: 21170267; PMCID: PMC3003138

Read More

ERG rearrangement metastasis patterns in locally advanced prostate cancer

David Rickman, PhD

ERG rearrangement metastasis patterns in locally advanced prostate cancer

Urology. 2010 Apr;75(4):762-7.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA.

PMID: 20018353; PMCID: PMC2850965

Read More

WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?

David Rickman, PhD

WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?

Genes Chromosomes Cancer. 2009 Sep;48(9):816-27.

Corbin M, de Reyniès A, Rickman DS, Berrebi D, Boccon-Gibod L, Cohen-Gogo S, Fabre M, Jaubert F, Faussillon M, Yilmaz F, Sarnacki S, Landman-Parker J, Patte C, Schleiermacher G, Antignac C, Jeanpierre C.

PMID: 19530245

Read More

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

David Rickman, PhD

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Neoplasia. 2009 Aug;11(8):804-11.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

PMID: 19649210; PMCID: PMC2713587

Read More

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

David Rickman, PhD

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Cancer Res. 2009 Apr 1;69(7):2734-8.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.

PMID: 19293179; PMCID: PMC4063441

Read More

Distinct genomic aberrations associated with ERG rearranged prostate cancer.

David Rickman, PhD

Distinct genomic aberrations associated with ERG rearranged prostate cancer.

Genes Chromosomes Cancer. 2009 Apr;48(4):366-80.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA.

PMID: 19156837; PMCID: PMC2674964

Read More

Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival

David Rickman, PhD

Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival

J Clin Oncol. 2009 Mar 1;27(7):1108-15.

de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J.

PMID: 19139432

Read More

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer

David Rickman, PhD

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer

Cancer Cell. 2008 Dec 9;14(6):471-84.

Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, Pontoglio M, Strick-Marchand H, Levillayer F, Nouet Y, Rickman D, Gauthier F, Branchereau S, Brugières L, Laithier V, Bouvier R, Boman F, Basso G, Michiels JF, Hofman P, Arbez-Gindre F, Jouan H, Rousselet-Chapeau MC, Berrebi D, Marcellin L, Plenat F, Zachar D, Joubert M, Selves J, Pasquier D, Bioulac-Sage P, Grotzer M, Childs M, Fabre M, Buendia MA.

PMID: 19061838

Read More

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays

David Rickman, PhD

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays

Oncogene. 2008 Nov 20;27(51):6607-22.

Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B.

PMID: 18679425

Read More

EML4-ALK fusion lung cancer: a rare acquired event

David Rickman, PhD

EML4-ALK fusion lung cancer: a rare acquired event

Neoplasia. 2008 Mar;10(3):298-302.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA.

PMID: 18320074; PMCID: PMC2259458

Read More

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.

David Rickman, PhD

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.

Blood. 2007 Jun 1;109(11):4952-63.

de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P.

PMID: 17284527

Read More

Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia

David Rickman, PhD

Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia

Blood. 2007 May 1;109(9):3972-81.

dos Santos NR, Rickman DS, de Reynies A, Cormier F, Williame M, Blanchard C, Stern MH, Ghysdael J.

PubMed PMID: 17192390

Read More

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

David Rickman, PhD

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

PLoS Med. 2007 Mar;4(3):e90.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PMID: 17388661; PMCID: PMC1831731

Read More

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

David Rickman, PhD

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

Blood. 2007 Mar 1;109(5):2156-64.

Lamant L, de Reyniès A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugières L, Gaulard P, Espinos E, Delsol G.

PMID: 17077326

Read More

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

David Rickman, PhD

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

Hepatology. 2007 Jan;45(1):42-52

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J.

PubMed PMID: 17187432

Read More

Apc tumor suppressor gene is the "zonation-keeper" of mouse liver

David Rickman, PhD

Apc tumor suppressor gene is the "zonation-keeper" of mouse liver

Dev Cell. 2006 Jun;10(6):759-70. 

Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S.

PubMed PMID: 16740478

Read More

Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis

David Rickman, PhD

Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis

Cancer Res. 2001 Sep 15;61(18):6885-91. 

Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM.

PubMed PMID: 11559565

Read More

The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant gliomas

David Rickman, PhD

The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant gliomas

Cancer Res. 2001 Mar 1;61(5):2162-8.

Rickman DS, Tyagi R, Zhu XX, Bobek MP, Song S, Blaivas M, Misek DE, Israel MA, Kurnit DM, Ross DA, Kish PE, Hanash SM.

PubMed PMID: 11280781

Read More

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192